Strs Ohio Lowers Holdings in Jazz Pharmaceuticals PLC $JAZZ

Strs Ohio trimmed its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 91.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,393 shares of the specialty pharmaceutical company’s stock after selling 14,393 shares during the quarter. Strs Ohio’s holdings in Jazz Pharmaceuticals were worth $184,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Vestal Point Capital LP bought a new position in Jazz Pharmaceuticals in the 2nd quarter worth about $127,344,000. AQR Capital Management LLC raised its holdings in Jazz Pharmaceuticals by 62.1% in the second quarter. AQR Capital Management LLC now owns 794,770 shares of the specialty pharmaceutical company’s stock worth $84,341,000 after buying an additional 304,463 shares during the last quarter. Allianz Asset Management GmbH lifted its stake in shares of Jazz Pharmaceuticals by 453.9% in the second quarter. Allianz Asset Management GmbH now owns 325,403 shares of the specialty pharmaceutical company’s stock worth $34,532,000 after buying an additional 266,658 shares in the last quarter. Boston Trust Walden Corp grew its holdings in shares of Jazz Pharmaceuticals by 129.1% during the second quarter. Boston Trust Walden Corp now owns 407,897 shares of the specialty pharmaceutical company’s stock valued at $43,286,000 after buying an additional 229,885 shares during the last quarter. Finally, Wedge Capital Management L L P NC bought a new stake in shares of Jazz Pharmaceuticals during the third quarter valued at approximately $27,834,000. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Trading Up 1.7%

Jazz Pharmaceuticals stock opened at $167.29 on Tuesday. The business has a 50-day simple moving average of $168.84 and a two-hundred day simple moving average of $144.30. The company has a market cap of $10.16 billion, a P/E ratio of -27.56, a P/E/G ratio of 0.89 and a beta of 0.26. Jazz Pharmaceuticals PLC has a 52-week low of $95.49 and a 52-week high of $182.99. The company has a quick ratio of 1.44, a current ratio of 1.65 and a debt-to-equity ratio of 1.09.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 77,500 shares of the company’s stock in a transaction that occurred on Wednesday, November 26th. The shares were sold at an average price of $177.81, for a total transaction of $13,780,275.00. Following the completion of the sale, the director directly owned 393,332 shares of the company’s stock, valued at approximately $69,938,362.92. This represents a 16.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Rick E. Winningham sold 5,500 shares of Jazz Pharmaceuticals stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $180.86, for a total transaction of $994,730.00. Following the transaction, the director owned 8,893 shares in the company, valued at $1,608,387.98. This represents a 38.21% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 123,791 shares of company stock valued at $21,991,850 in the last three months. Corporate insiders own 4.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Robert W. Baird upped their price objective on Jazz Pharmaceuticals from $160.00 to $209.00 and gave the company an “outperform” rating in a research report on Tuesday, November 18th. UBS Group reaffirmed a “neutral” rating and set a $188.00 price objective (up from $163.00) on shares of Jazz Pharmaceuticals in a research report on Monday, November 24th. Truist Financial lifted their price objective on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a report on Monday, January 12th. TD Cowen restated a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Thursday. Finally, JPMorgan Chase & Co. reduced their price target on shares of Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating for the company in a research note on Monday, October 27th. Fourteen research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $205.67.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.